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The cytochrome P450 (CYP)4F2 gene is known to influence mean coumarin dose. The aim of the present study was 
to undertake a meta- analysis at the individual patients level to capture the possible effect of ethnicity, gene—gene 
interaction, or other drugs on the association and to verify if inclusion of CYP4F2*3 variant into dosing algorithms 
improves the prediction of mean coumarin dose. We asked the authors of our previous meta- analysis (30 articles) 
and of 38 new articles retrieved by a systematic review to send us individual patients’ data. The final collection 
consists of 15,754 patients split into a derivation and validation cohort. The CYP4F2*3 polymorphism was 
consistently associated with an increase in mean coumarin dose (+9% (95% confidence interval (CI) 7–10%), with a 
higher effect in women, in patients taking acenocoumarol, and in white patients. The inclusion of the CYP4F2*3 in 
dosing algorithms slightly improved the prediction of stable coumarin dose. New pharmacogenetic equations 
potentially useful for clinical practice were derived.
Coumarins have proved to be effective in the treatment of throm-
boembolic disease and despite the introduction of direct oral anti-
coagulants, they remain one of the most widely prescribed family 
of drugs worldwide.1
The narrow therapeutic index and high interindividual vari-
ability in therapeutic dose make coumarin therapy difficult to 
manage. Many studies have showed two genes, cytochrome P450 
(CYP)2C9 and VKORC1, which are associated with variation 
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in warfarin, phenprocoumon, and acenocoumarol maintenance 
doses requirement and have suggested some clinical benefits from 
genotype- guided dosing.2 On the basis of such data, the US Food 
and Drug Administration has updated the label for warfarin twice, 
advising that two variants in the CYP2C9 gene (C144R and I359L) 
and one in the Vitamin K epOxide Reductase Complex subunit 1 
(VKORC1) gene (G- 1639A) might be taken into consideration 
when initiating warfarin therapy (warfarin product labeling, US 
Food and Drug Administration https://www.accessdata.fda.gov/
drugsatfda_docs/label/2011/009218s107lbl.pdf ).
Although there have been contradictory results in randomized 
clinical trials (RCTs) about the utility of genotype- guided dosing 
of coumarin drugs when compared with either standard clinical 
care or clinical algorithms,3–5 a recent RCT in patients under-
going elective hip or knee arthroplasty6 showed superiority of 
genetic dosing compared with clinical dosing. Some, but not all, 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Coumarin drugs have a narrow therapeutic index, but sin-
gle-nucleotide polymorphisms (SNPs) in the cytochrome P450 
(CYP2)C9 and VKORC1 genes may help in predicting the dose.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Do genetic algorithms, including the CYP4F2*3 SNP, 
 perform better than old ones in predicting mean coumarin 
dose?
WHAT DOES THIS STUDY ADD TO OUR 
KN O W LEDGE?
 In this single- patient meta- analysis, we confirm that 
CYP4F2*3 influences mean coumarin dose especially in 
women, in patients taking acenocoumarol, and in white pa-
tients but with a low effect size.
HOW MIGHT THIS CHANGE CLINICAL PHA­
RMACOLOGY OR TRANSLATIONAL SCIENCE?
 New pharmacogenetic equations potentially useful for clini-
cal practice have been derived for different ethnic groups.
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meta- analyses have also shown an improvement in clinical end 
points, such as bleeding events.3,7–11 Moreover, none of the trials 
included in the meta- analyses included CYP4F2*3 polymorphism 
(1347C>T; c.1297G>A; p.Val433Met; rs2108622), whose ef-
fect on coumarin dose was discovered later when compared with 
CYP2C9 and VKORC1.
Our previous meta- analysis performed on aggregate data from 
30 studies showed that CYP4F2 variation was associated with 
nearly 8% higher coumarin doses in T allele carriers. Indeed, a 
possible gene–gene interaction and an effect of race on the ge-
netic effect were detected.12 Despite the low effect size, CYP4F2 
is currently regarded as the third most influential genetic locus 
with respect to coumarin drug maintenance dose. Older studies, 
which compared pharmacogenetic algorithms with either clinical- 
based algorithms or fixed- dose approach, did show a possible 
improvement in prediction only in selected subgroups.13,14 The 
incorporation of CYP4F2 into existing models might improve 
the accuracy of dose prediction with coumarins.15,16 Recently, the 
Clinical Pharmacogenetics Implementation Consortium updated 
the guidelines for CYP2C9 and VKORC1 genotypes and warfa-
rin dosing, including evidence from the published literature for 
the nonsynonymous variant CYP4F2*3 (1347C>T; c.1297G>A; 
p.Val433Met; rs2108622), which was found to be significantly as-
sociated with altered dose requirements for coumarin anticoagu-
lants.2 In order to clarify the actual clinical utility of including the 
CYP4F2 polymorphism into pharmacogenetic dosing algorithms, 
some essential information is needed. Thus, we performed a meta- 
analysis at the individual patients level to understand the real effect 
size of this polymorphism and to test how much either a possible 
gene–gene interaction or the effect of ethnicity or other covariates 
could modify the pharmacogenetic association and prove to be 
useful in creating new pharmacogenetic equations. We hereby pro-
vide the largest meta- analysis of CYP2C9, VKORC1, and CYP4F2 
polymorphisms affecting the dose of warfarin and acenocoumarol 
in samples collected from 25 different countries, including more 
than 15,000 participants treated with coumarin drugs. New phar-
macogenetic equations potentially useful for clinical practice have 
been derived for different ethnic groups.
RESULTS
Characteristics of included studies
Starting from the 30 articles included in our previous meta- 
analysis (search from inception until August 2011), individual pa-
tient data were obtained from 19 studies.17–35 From one coauthor 
we obtained an additional dataset related to an article not previ-
ously included because no data about the CYP4F2 polymorphism 
were present in the original publication.36 From the group of 38 
articles retrieved from the new search (from September 1, 2011, to 
September 14, 2016), individual patient data were obtained from 
18 studies (Figure 1).15,16,37–52
Thus, 38 articles were included in the present work from au-
thors who agreed to share individual patient data: 20 from the first 
systematic search and 18 from the second systematic search. Data 
from one study were divided into two distinct cohorts according to 
the main author’s subdivision of sample into discovery and valida-
tion cohorts.46 Moreover, data from two studies had been collected 
in one cohort.15,43 Finally, data from one study was divided into 
two cohorts: one cohort treated with acenocoumarol and the other 
with phenprocoumon treatment.44 This resulted in 39 cohorts that 
were considered for the meta- analysis, including a total of 15,754 
patients. Characteristics of the individual studies are summarized 
in Table 1. Thirty- one cohorts examined the association between 
CYP4F2 polymorphism and the maintenance dose of warfarin; 
seven cohorts evaluated this association for acenocoumarol and 
one for phenprocoumon. Information on CYP4F2, VKORC1, 
and CYP2C9*3 genotyping were available for all 39 cohorts, 
whereas CYP2C9*2 genotype was recorded for 35 of the 39 co-
horts (89.7%). All studies but one19 included both male and female 
participants with a minimum of 24% men. One study selected very 
elderly patients (mean age 86.7 years).35 Data on body mass index 
(BMI) and drugs known to potentially interfere with warfarin 
were available for 31 and 27 cohorts, respectively. All studies were 
published between 2006 and 2016.
Association between CYP4F2*3 polymorphism and stable 
coumarin dose
Figure 2 shows the forest plot for the difference in log dose of war-
farin for subjects with at least one T allele (CT + TT) CYP4F2 
as compared to wild- type (CC) subjects, according to a dominant 
model. The estimated effect size was 0.09 (95% confidence inter-
val (CI) 0.07–0.10), corresponding to a 9% increase in mg/week 
(95% CI 7–10%). The funnel plot (see Figure S1) is compatible 
with no effect of bias on publication.
Separate estimates for CT and TT CYP4F2 genotypes are re-
ported in Figure S2: the estimated effect size for CT vs. CC sub-
jects is 0.07 (95% CI 0.06–0.08), corresponding to a 7% increase 
in mg/week; whereas for TT vs. CC subjects it is 0.17 (95% CI 
0.15–0.19), corresponding to a 19% increase in mg/week. In 
Table 2, the analysis of the available subgroups highlights that the 
effect of the CYP4F2*3 polymorphism is significant in whites and 
Asians but not in blacks and other ethnic groups. Moreover, there 
was a significant difference by gender for the effect of the CYP4F2 
polymorphism on coumarin dose (the effect is significantly higher 
in women) and by type of coumarin drugs (the effect was lower 
for warfarin as compared to acenocoumarol). No significant dif-
ference in the effects of smoking, target International Normalized 
Ratio (INR), adjustment for other drugs, consistency of genotype 
frequencies with the Hardy- Weinberg equilibrium, quality score, 
and other polymorphisms was found (Table 2). The figures for the 
different meta- analyses in subgroups are presented in Figures S3 
and S4.
Stable coumarin dose predictive model
Table 3 presents the predictive model for logarithm of stable 
coumarin dose according to patients’ clinical and genetics charac-
teristics. As statistical test for model fit (R2) is reported for both 
the test and validation cohorts. Looking at our calculated model 
on the whole dataset, adjusted R2 was slightly higher for models 
including CYP4F2*3 polymorphisms than for models without 
CYP4F2*3 for all the ethnic groups except blacks (for warfarin 
dose, adjusted R2 for models with and without CYP4F2*3 poly-
morphism were, respectively, 0.51 and 0.50 for whites, 0.43 and 
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0.42 for Asians, and 0.27 and 0.27 for blacks). For cohorts that 
included black patients, addition of the CYP2C9*5 single-nucleo-
tide polymorphism (SNP) to the models did not result in substan-
tial improvement of the adjusted R2 (Table 3). Further prediction 
models also including concomitant drugs (amiodarone, etc.) and 
smoking habits are presented in Table S1.
Beta coefficients for single-gene and gene–gene interaction are 
presented in Table 4 for each ethnicity and drug subgroups.
The effect of potentially interacting drugs could be evaluated 
only on a subsample of the cohorts and is presented in Table S2. 
Patients taking amiodarone or drugs classified as CYP inhibitors 
required a lower dose, whereas patients taking CYP inducers re-
quired a higher dose of coumarin drugs. If the effect of the drugs 
was considered, the beta estimate for CYP4F2 and the other SNPs 
varied slightly but remained significant for most analyses. No sig-
nificant interaction between SNPs and drugs were detectable apart 
from CYP2C9*2 and rifampin and all CYP inhibitors and all CYP 
inducers in white patients consuming acenocoumarol. Another 
weak but nominally significant interaction was present between 
CYP2C9*2 and statin or aspirin in black patients on chronic war-
farin therapy (Table S2).
The comparison of R2 of our model with those calculated for 
two previously published models are reported in Table S3 and are 
basically comparable, ranging from 0.41−0.47 for whites, 0.44 for 
Asians, and from 0.23−0.33 for blacks.
DISCUSSION
In our previous meta- analysis on the effect of the CYP4F2 
rs2108622 (1347C>T; c.1297G>A; p.Val433Met; CYP4F2*3), 
we found that the estimated effect size was nearly 10%. In this 
individual patient data meta- analysis, we have not only confirmed 
this finding in a larger cohort of primary studies that include all 
the available study- specific covariates but can add other important 
findings. Contrary to what was found in the first meta- analysis, 
a slight but significant effect of gender was identified such that 
men had a lower effect of the T allele when compared to women. 
Figure 1 Flow diagram. CRT, controlled randomized trial; CYP4F2, cytochrome P450 F2. [Colour figure can be viewed at wileyonlinelibrary.com]
Records identified by searching database for key words 
(1st of September 2011–16 th of September 2016):  
PubMed: 512 
Web of science: 395 
Records screened: titles or abstracts n = 642 
Records excluded n = 573 
Not related to coumarin drugs or CYP4F2, or allelic 
frequency analysis, or sample selected on the basis of 
response to warfarin, or CRT or children or duplicate 
samples: 449                     
Reviews, editorials, guidelines, books selection, case 
reports, comments: 124 
Full text articles assessed for eligibility n = 66 
Records excluded n = 28 
Duplicate of data sets: 11 
CRT: 2
Meta-analysis: 1 
Validation of algorithms: 3
No stable dose/no coumarin drugs: 9 
Selected population according to sensitivity to 
coumarin drugs: 1
No CYP4F2: 1
Articles potentially elegible n = 38 Previous meta-analysis by Danese et al. n = 30 
(published before 1st September 2011) 
Duplicates excluded (n = 265) 
Articles included because authors sent 
individual patient data n = 18 
Articles included because authors sent 
individual patient data n = 20  
(including Aquilante et al. 2006) 
Articles included in the individual 
patient data meta-analysis n = 38 
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Indeed, a higher dose of coumarin drugs was needed in carriers of 
the T allele if they were whites or Asians but not in blacks or in 
other ethnic groups (Indians, browns from Brazil, and Egyptians), 
but the latter is probably a reflection of the lower sample size. We 
also identified differences between different coumarin drugs: pa-
tients taking acenocoumarol and carrying the T allele needed a 
higher dose of the drug when compared with patients taking war-
farin and carrying the same polymorphism.
There was no effect of other possible important covariates, such 
as smoking, age, and indication for coumarin, and no interactions 
with the other relevant polymorphisms were found.
Evaluation of the beta estimate of the tested SNPs confirmed 
that the larger effect is due to the VKORC1 followed by CYP2C9, 
whereas CYP4F2 had a limited effect size.
Looking at primary studies, the large majority of them are in line 
with the results of the meta- analysis, and only 4 of the 39 have a 
central point of the estimate below the 0 line. Even the point esti-
mate for the effect of CYP4F2 is not so different between primary 
studies. The extremes are the study performed by Borgiani et al.18 
with a + 0.26 estimate and the one by Isaza et al.48 with a −0.05, 
which have a 95% CI that is around + 0.07, not far from our total 
effect size (slightly < 10%).
However, the funnel plot shows a certain asymmetry, almost 
significant when analyzed using Egger’s test. It is therefore pos-
sible that unpublished negative studies could affect the real esti-
mate of the effect of the CYP4F2*3 polymorphism.
Differently from our previous meta- analysis, we could also add 
drugs as moderating parameters at least in some subgroups, and as 
expected, this evaluation decreased heterogeneity.
The functionality of the CYP4F2 polymorphism has been 
shown in relation to the production of 20-hydroxyeicosatetraenoic 
acid derived by arachidonic acid and in differences in mRNA pro-
duction by liver cells in carriers of different alleles.53
The interaction of the CYP4F2 polymorphism with gender is 
not unexpected: also in other studies exploring other cardiovascu-
lar actions, some CYP polymorphisms have shown a differential ef-
fect in men and women probably due to an interaction with either 
androgens or estrogens.54 Even in animal models these differences 
are evident, at least for blood pressure determination.54
Due to our large sample size, we could calculate and subse-
quently validate different prediction models that included the 
effect of the CYP4F2*3, the other well- known polymorphisms 
of CYP2C9 and VKORC1, and the other covariates differenti-
ating the effect of gender and ethnicity and obtaining discrete 
Figure 2 Forest plot for the difference in logarithm of stable coumarin dose* for subjects with cytochrome P450 (CYP)4F2 polymorphism (CT + TT) 
compared with subjects with (CYP)4F2 wild- type (CC), according to dominant model. [Colour figure can be viewed at wileyonlinelibrary.com]
CI=Confidence Intervals; ES=Estimate 
* exp(ES) gives the relative percentage difference as weekly dose in mg
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coefficient of determinations that indicate a good fit of the models. 
Other predictive pharmacogenetic equations estimating coumarin 
dose have been developed using large samples sizes,13,14 but both 
the International Warfarin Pharmacogenetics Consortium and the 
“Warfarin dosing” equations used only CYP2C9 and VKORC1 ge-
netic variation to estimate warfarin dose and the R2 estimate for the 
final model (which also included amiodarone), obtaining values of 
0.47 and 0.53, respectively. These results are in line with our data 
for white subjects, but our results are more generalizable because 
multiple cohorts from Europe were also included. In fact, Gage’s 
equation is derived from a more homogeneous group of patients col-
lected in three centers in the United States (St. Louis, San Antonio, 
and Gainesville) with a fourth trial included in the validation co-
hort.13 By contrast, the International Warfarin Pharmacogenetics 
Consortium collected 21 research groups from 9 different coun-
tries and finally included only patients with a target INR between 
2 and 3 (n = 5,052). Their final model was not divided according 
to ethnicity but instead the ethnicity variable was added in the 
model. Indeed, outlier patients were excluded from the final analy-
sis. It is worth mentioning that the final sample size of our study is 
more than two times the previous studies for warfarin, and we have 
also calculated predictive models for acenocoumarol.
Even if newer anticoagulants have substantially changed clini-
cal practice, especially in developed countries, the use of coumarin 
drugs is still widespread in the world, so that equations like the one 
derived from our study will be clinically useful for many years. The 
importance of genotype has been further shown in the Effective 
aNticoaGulation with factor xA next GEneration in Atrial 
Fibrillation-Thrombolysis In Myocardial Infarction (ENGAGE 
AF- TIMI) 48 trial, which compared the clinical efficacy of edox-
aban, a direct oral anticoagulant, with warfarin in a prespecified ge-
netic subanalysis. Stratification of patients according to CYP2C9 
and VKORC1 polymorphisms revealed that of the three groups 
identified, normal responders, sensitive responders, and highly 
sensitive responders, the last group was found to spend a greater 
proportion of time over- anticoagulated compared with normal re-
sponders but only for the first 90 days of treatment.55
RCTs using not only the CYP2C9 and VKORC1 poly-
morphism but also the CYP4F2 polymorphism have recently 
been performed. In nonvalvular atrial fibrillation, no apparent 
Table 2 Subgroup analyses of association studies of the CYP4F2 polymorphism on coumarin dose requirements
Variable Subgroup (N studies) Differencea (95% CI) I2 (Q test F value)
Meta regression 
P value
Ethnicity Whites (26) 0.10 (0.08−0.11) 15% (0.25) 0.002
Asians (10) 0.08 (0.05−0.11) 0% (0.85) 0.02
Blacks (5) 0.05 (−0.04; 0.14) 21% (0.28) 0.36
Others (5)b 0.01 (−0.05; 0.06) 0% (0.72) Reference
Drug Acenocoumarol (7) 0.11 (0.09−0.13) 13% (0.33) 0.03
Warfarin (31) 0.08 (0.06−0.09) 9% (0.33)
Sex Males (39) 0.07 (0.06−0.09) 16% (0.20) 0.03
Females (38) 0.10 (0.08−0.12) 19% (0.16)
INR target < 2.5 (11) 0.08 (0.05−0.11) 0% (0.79) Reference
2.5 (23) 0.09 (0.07−0.11) 22% (0.17) 0.42
> 2.5 (18) 0.08 (0.06−0.10) 0% (0.49) 0.93
Smoking No (21) 0.09 (0.07−0.11) 0% (0.68) 0.74
Yes (12) 0.07 (−0.02; 0.15) 33% (0.12)
Other drugs considered No (7) 0.08 (0.03−0.12) 47% (0.08) 0.72
Yes (32) 0.09 (0.08−0.10) 10% (0.31)
Hardy- Weinberg equilibrium No (6) 0.08 (0.04−0.12) 53% (0.06) 0.92
Yes (33) 0.09 (0.07−0.10) 9% (0.33)
Quality score < 5 0.08 (0.06−0.10) 29% (0.11) 0.46
≥ 5 0.09 (0.08−0.11) 6% (0.39)
CYP2C9 CYP2C9 *1*1 0.08 (0.07−0.10) 18% (0.18) 0.73
CYP2C9 *1*2/ 
*1*3/*2*2/*2*3/*3*3
0.09 (0.06−0.12) 25% (0.10)
VKORC11 VKORC1 GG 0.08 (0.06−0.10) 4% (0.40) 0.13
VKORC 
1 AA/AG
0.10 (0.08−0.11) 10% (0.30)
Data in bold are significant at P < 0.05.
CI, confidence interval; CYP, cytochrome P450; INR, International Normalized Ratio.
aDifference in logarithm of stable coumarin dose of subjects with CYP4F2 polymorphism (CT + TT) compared with subjects with CYP4F2 wild- type (CC), according 
to dominant model. bIncludes Indian, Egyptian, brown, and Hispanic.
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advantage was found for the group randomized to genotype base 
dose,56 but in a recent trial in patients aged 65 years or older ini-
tiating warfarin for elective hip or knee arthroplasty conducted at 
six US medical centers, genotyping reduced the combined risk of 
major bleeding, INR of 4 or greater, venous thromboembolism, 
or death.6
In another trial that compared a genotype- guided algorithm 
vs. physician management for the initiation of acenocoumarol, a 
higher proportion of patients in the genetic group reached and 
maintained a steady dose than patients randomized to routine 
practice when starting oral anticoagulation.57
Limitations and strengths of the study
Our individual data meta- analysis has limitations. First, although 
we applied a sensitive search strategy for the retrieval of potentially 
eligible studies, we cannot rule out the possibility that some relevant 
studies might not have been included. Indeed, not all the potentially 
eligible studies were added to the meta- analysis because the authors 
did not share individual patients’ data. Second, adjustment for cer-
tain covariates, such as amiodarone, was possible in only a limited 
sample of patients. The quality score of the included studies was het-
erogeneous, ranging from 3−7 (median: 5), but this did not affect 
CYP4F2*3– coumarin dose association, because we found no statis-
tically significant difference in the estimates for studies with lower 
and higher quality score. Finally, our genotyping- based algorithms 
in blacks have low predictivity even including the CYP2C9*5 poly-
morphism, probably because we could not include more variants in 
CYP2C9 that were demonstrated to be especially important in this 
ethnic group.2 Because the exclusion of specific CYP2C9 variants 
from the dosing algorithm in blacks can lead to overdosing, we would 
recommend against the use of the specific dosing algorithms in pa-
tients of African ancestry2 until more specific algorithms have been 
developed.
Strengths of our collaborative study are the large sample size 
with several ethnic groups allowing for generalizability of the re-
sults and the possibility to have equations not only for warfarin 
but also for acenocoumarol based on a quite large sample size. The 
heterogeneity was low possibly because most of the variables as-
sociated with mean coumarin dose have been considered in our 
models.
CONCLUSION
In conclusion, we have undertaken the largest individual patient data 
meta- analysis, including the CYP4F2 polymorphism, in patients 
taking warfarin or other coumarin drugs. Our data show that the 
CYP4F2 rs2108622 polymorphism affects the dose requirements of 
these drugs in whites and Asians but not in blacks or other ethnic 
groups. We also provide reliable prediction models, which can guide 
physicians to estimate the stable dose of warfarin according to gen-
otypes, anthropometric and demographic factors, ethnicity, and the 
use of other drugs.
Regardless, because RCTs that tested genetic prediction mod-
els with the CYP4F2*3 SNP showed contradictory results,6,56 the 
utility of these models in clinical practice needs to be established 
in further RCTs before their widespread utilization in clinical 
settings.Ta
bl
e 
4
 B
et
a 
co
ef
fic
ie
nt
s 
(P
 v
al
ue
s)
 f
or
 s
in
gl
e 
ge
ne
s 
an
d 
ge
ne
–g
en
e 
in
te
ra
ct
io
n
E
th
ni
ci
ty
D
ru
g
N
 s
ub
je
ct
s 
(N
 s
tu
di
es
)
C
YP
4
F2
C
YP
2
C
9
VK
O
R
C
1
C
YP
4
F2
*C
YP
2
C
9
C
YP
4
F2
*V
K
O
R
C
1
C
YP
2
C
9*
VK
O
R
C1
W
hi
te
s
Ac
en
oc
ou
m
ar
ol
4
,1
5
4
 (
5
)
0
.0
8
 (
0
.0
0
0
2)
−
0
.2
2
 (
<
 0
.0
0
0
1)
−
0
.4
0
 
(<
 0
.0
0
0
1)
−
0
.0
2
 (
0
.5
1)
−
0
.0
3
 (
0
.2
1)
−
0
.0
1
 (
0
.7
9
)
W
ar
fa
ri
n
4
,5
4
8
 (1
5
)
0
.0
8
 (
0
.0
0
0
1)
−
0
.3
0
 (
<
 0
.0
0
0
1)
−
0
.3
8
 
(<
 0
.0
0
0
1)
−
0
.0
0
1
 (
0
.9
6
)
0
.0
2
 (
0
.3
7
)
−
0
.0
1
 (
0
.5
5
)
As
ia
ns
Ac
en
oc
ou
m
ar
ol
0
 (
0
)
N
E
N
E
N
E
N
E
N
E
N
E
W
ar
fa
ri
n
4
3
8
 (
8
)
0
.1
0
 (
0
.3
4)
−
0
.2
6
 (
0
.0
5
)
−
0
.4
6
 
(<
 0
.0
0
0
1)
0
.1
2
 (
0
.3
6
)
−
0
.0
8
 (
0
.4
8
)
−
0
.0
0
4
 (
0
.9
8
)
B
la
ck
s
Ac
en
oc
ou
m
ar
ol
0
 (
0
)
N
E
N
E
N
E
N
E
N
E
N
E
W
ar
fa
ri
n
8
1
5
 (
5
)
0
.0
4
 (
0
.3
0
)
−
0
.2
0
 (
0
.0
0
0
4)
−
0
.2
7
 
(<
 0
.0
0
0
1)
0
.0
0
4
 (
0
.9
7
)
−
0
.0
2
 (
0
.8
2)
0
.0
2
 (
0
.8
3)
O
th
er
s
Ac
en
oc
ou
m
ar
ol
0
 (
0
)
N
E
N
E
N
E
N
E
N
E
N
E
W
ar
fa
ri
n
70
1
 (
7
)
−
0
.0
8
 (
0
.1
3)
−
0
.1
9
 (
0
.0
0
3)
−
0
.2
7
 
(<
 0
.0
0
0
1)
0
.0
7
 (
0
.3
1)
0
.0
9
 (
0
.1
3)
−
0
.0
5
 (
0
.4
8
)
Al
l
Al
l
1
1
,4
3
5
 (2
9
)
0
.0
7
 (
<
 0
.0
0
0
1)
−
0
.2
4
 (
<
 0
.0
0
0
1)
−
0
.3
7
 
(<
 0
.0
0
0
1)
0
.0
2
 (
0
.2
1)
0
.0
2
 (
0
.2
3)
−
0
.0
2
 (
0
.1
2)
D
at
a 
in
 b
ol
d 
ar
e 
si
gn
if
ic
an
t 
at
 P
 <
 0
.0
5
.
Et
hn
ic
it
y-
 sp
ec
if
ic
 a
nd
 d
ru
g-
 sp
ec
if
ic
 m
od
el
s 
ar
e 
ad
ju
st
ed
 b
y 
st
ud
y,
 a
ge
, 
ge
nd
er
, 
bo
dy
 m
as
s 
in
de
x,
 a
nd
 in
di
ca
ti
on
 f
or
 t
re
at
m
en
t.
 T
he
 f
in
al
 m
od
el
 is
 a
ls
o 
ad
ju
st
ed
 b
y 
et
hn
ic
it
y 
an
d 
dr
ug
. 
Fo
r 
ea
ch
 g
en
e,
 t
he
 r
ef
er
en
ce
 
ca
te
go
ry
 is
 t
he
 g
en
e 
po
ly
m
or
ph
is
m
 a
cc
or
di
ng
 t
o 
th
e 
do
m
in
an
t 
m
od
el
 (
he
te
ro
zy
go
us
 +
 v
ar
ia
nt
 h
om
oz
yg
ou
s 
vs
. 
w
t)
. 
Fo
r 
th
e 
an
al
ys
is
 o
n 
bl
ac
ks
, 
C
YP
2
C
9
 in
cl
ud
ed
, 
be
yo
nd
 *
2
 a
nd
 *
3
, 
al
so
 *
5
 p
ol
ym
or
ph
is
m
.
C
Y
P,
 c
yt
oc
hr
om
e 
P4
5
0
; 
N
E,
 n
ot
 e
st
im
at
ed
.
ARTICLE
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 105 NUMBER 6 | June 2019 1489
METHODS
Search strategy and eligibility criteria
The 30 articles included in our previous meta- analysis were consid-
ered all potentially eligible for the present study.12 To expand our 
search to articles published after the date fixed for final inclusion in 
the previous meta- analysis, we searched Medline and Web of Science 
from September 1, 2011, to September 14, 2016, by applying the same 
search algorithm used previously (see Supplementary Material S1) 
and found 38 additional studies that could potentially be included 
(see Figure 1) according to the inclusion criteria (see Supplementary 
Material S1). All 68 studies evaluated for inclusion were clinical cohort 
or cross- sectional studies that have performed genotyping of CYP4F2 
in combination with CYP2C9 (at least one of the two variants of in-
terest) and/or VKORC1 in coumarin- treated patients. As per our pre-
vious study, we considered the following polymorphisms: rs2108622 
(1347C>T; 1297G>A; p.Val433Met; CYP4F2*3) for CYP4F2, 
rs1799853 (430C>T) and rs1057910 (1075A>C) for CYP2C9 (also 
known as CYP2C9*2 and CYP2C9*3), and rs9923231 (−1639 G>A) 
for VKORC1. In relation to the latter variant, we also included data 
from studies that used the two alternative polymorphisms: rs9934438 
(1173C>T) in the VKORC1 gene, which is in complete linkage disequi-
librium with the reference polymorphism and rs10871454 (−1168C>T) 
located in the Syntaxin 4 A- placental (STX4A) gene, f lanking the 
VKORC1 gene, which showed a linkage disequilibrium of 0.99 with 
the reference polymorphism.
In our previous analysis, consistent with published studies, the perfor-
mance of our regression was low, especially in black subjects, in which an 
effect of other SNPs especially in CYP2C9 is considered important. Thus, 
in the five cohorts in which at least the CYP2C9*5 variant was available we 
repeated the analysis by adding this polymorphism.
Data collection
We asked the first/last or corresponding authors of the retrieved pri-
mary studies to participate in a collaborative meta- analysis on individ-
ual patient data. Authors who were willing to collaborate were finally 
included if their original database contained the following mandatory 
data for single patients: gender, age, race, genotypes, indication for cou-
marin therapy, INR target, type of coumarin used, and maintenance 
dose. Additional information on body weight, height, and use of inter-
acting drugs were also recorded when available. Each cohort has been 
assigned to one single study unless otherwise specified. For studies con-
taining overlapping samples we considered the first published study or 
the one that enrolled the largest number of patients. Data were harmo-
nized into a pooled database. Two researchers (E.D. and M.M.) cross- 
checked trial details provided by the authors against published articles. 
Any inconsistencies were discussed with the original trialists, and cor-
rections were made when appropriate. As for our previous meta- analysis, 
we graded the quality of epidemiologic studies in general, applying 
items taken from the Newcastle–Ottawa Quality Assessment Scale for 
Cohort Studies indicators specific to the quality of genetic association 
studies, and indicators specific for coumarin (e.g., stable anticoagula-
tion). Quality assessment also included departure from Hardy- Weinberg 
equilibrium that was calculated by the χ2 test in controls. We applied 
a scale with a maximum score of seven points (see Supplementary 
Material S1 for details).
Statistical analysis
Two- stage analysis for the association between CYP4F2*3 
polymorphism and stable coumarin dose. We calculated study- 
specific estimates, with 95% CIs, for the difference in log dose of couma-
rin for subjects with at least one CYP4F2 T allele (CT + TT) compared 
to wild- type (CC) subjects, according to a dominant model. Separate 
estimates for CT and TT genotypes were also calculated as a sensitivity 
analysis. These study- specific estimates were obtained by fitting general 
linear models with log dose of coumarin as the dependent variable and 
CYP4F2*3 polymorphism as the independent variable. All the models 
were adjusted for available study- specific covariates, including age, gender, 
race, BMI, smoking status, indication for coumarin treatment, INR target, 
concomitant drugs, CYP2C9*2 and *3 polymorphisms, and VKORC1 
polymorphism.
Following the two- stage analysis approach, we pooled study- specific 
estimates with random- effects models, using the DerSimonian and 
Laird method (see Supplementary Methods S1). We evaluated ho-
mogeneity among study- specific estimates by the Q statistic and I2, 
which represents the percentage of total variation across studies that is 
attributable to heterogeneity rather than to chance (see Supplementary 
Methods S1). We performed metaregression analysis to assess the in-
fluence on Summary Estimates of different study features: type of 
drugs (acenocoumarol/warfarin), gender, ethnicity (whites/Asians/
blacks/others), INR target (< 2.5/2.5/> 2.5), current smoking sta-
tus, study adjustment for concomitant drugs (yes/no), deviation from 
Hardy- Weinberg equilibrium, quality score (< 5/≥ 5), CYP2C9*2/*3 
(wild- type/any polymorphism), and VKORC1 (wild- type/any poly-
morphism). When significant differences according to specific study 
factors were suggested by metaregression, stratified analyses were per-
formed for CYP4F2*3– coumarin dose association on subgroups of sig-
nificant factors.
We assessed possible participation bias by drawing funnel plots and by 
Egger’s test (see Supplementary Methods S1).
The P values < 0.05 were considered statistically significant for all the 
tests apart from the Q statistic, where P values < 0.10 were considered 
statistically significant. The analysis was carried out using the SAS (SAS 
Institute Inc, Cary, NC ) version 9.4 and STATA (StataCorp, College 
Station, TX) version 13 software.
Stable coumarin dose predictive model. Due to significant differences 
in coumarin dose and CYP4F2*3 association for different drugs and 
ethnic groups, the individual data analysis on the pooled dataset was always 
reported for each type of drug (acenocoumarol/warfarin) and for each 
ethnic group.
For each ethnic and drug subgroup, we randomly chose 2/3 of pa-
tients as the “derivation cohort” for developing dose- prediction models, 
whereas the remaining 1/3 of the patients constituted the “validation 
cohort,” which was used for testing the final selected model. In order to 
keep a large sample size for prediction model construction, we included 
covariates that were available in the majority of studies (Table 1): age, 
BMI, gender, indication for treatment, CYP4F2*3, CYP2C9*2, *3, and 
*5 (for blacks), and VKORC1 polymorphisms, by using general linear 
models with log dose of coumarin as dependent variable. To use an ad-
ditive genetic model, we coded the number of variant alleles at each 
locus as 0, 1, or 2. Sensitivity analyses were also conducted on the whole 
cohort of subjects by including further available covariates collected in 
a smaller number of studies (concomitant drugs, especially amiodarone, 
and smoking status) to assess their role in stable coumarin dose pre-
diction. The coefficient of determination (R2) was calculated both for 
the main prediction model on the “derivation cohort” and for models 
included in sensitivity analyses. We applied the scores obtained from 
the main prediction model to the validation dataset and also calculated 
the R2.
For the sake of comparison, we also applied scores obtained from two 
previously published models for warfarin dose prediction13,14 to our val-
idation cohort and converted the scores to units of mg/week. In order 
to correctly compare our proposed model with each of the two previ-
ously published models, R2 was calculated on the subset of subjects for 
whom both scores could be calculated on the basis of available data. In 
order to assess the importance of CYP4F2*3 on warfarin dose prediction 
in our data, we also compared dose predictions from our pharmacog-
enetic model, including CYP4F2*3 in the whole dataset with that from 
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our model excluding CYP4F2*3 by using the adjusted R2 as defined by 
Darlington (see Supplementary Methods S1).
Gene–gene and gene–drug interactions were investigated by adding an 
interaction term to the main prediction model fitted on the whole cohort 
of subjects (for each drug/ethnicity subgroup) in order to have the largest 
sample size to test for interaction. Moreover, we performed subgroup ana-
lyses according to the use or not of specific concomitant drugs, to evaluate 
whether the change in coumarin dose associated with specific gene poly-
morphisms were modified by concomitant drugs.
The assumption of exchangeability for this analysis was briefly discussed 
in the Supplementary Methods S1. The P values < 0.05 were considered 
statistically significant. The analyses were carried out using SAS version 
9.4 software. The SAS code is available as Supplementary Material S1.
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com).
Figure S1. Funnel plot for association studies of the CYP4F2 polymor-
phism on coumarin dose.
Figure S2. Forest plot for the difference in logarithm of stable couma-
rin dose* for subjects with (a) CYP4F2 polymorphism (CT) compared 
to subjects with CYP4F2 wild- type (CC), (b) CYP4F2 polymorphism (TT) 
compared with subjects with CYP4F2 wild- type (CC).
Figure S3. Forest plot for the difference in logarithm of stable coumarin 
dose* for subjects with CYP4F2 polymorphism (CT + TT) compared to 
subjects with CYP4F2 wild- type (CC), according to dominant model and 
stratified by (A) ethnicity; (B) drug; (C) gender.
Figure S4. Forest plot for the difference in logarithm of stable coumarin 
dose* for subjects with CYP4F2 polymorphism (CT + TT) compared with 
subjects with CYP4F2 wild- type (CC), according to dominant model and 
stratified by (A) CYP2C9; (B) VKORC1.
Table S1. Predictive models for logarithm of INR dose according to 
patients’ clinical and genetics characteristics: sensitivity analysis in-
cluding different models.
Table S2. Effect of concomitant drugs on warfarin dose and genetic 
polymorphisms of CYP4F2 and CYP2C9 genes: gene− drug interaction 
and subgroup analyses.
Table S3. Statistical test for model fit (R2) of two previously published 
models for warfarin dose prediction (Gage 2008, Klein 2009) in com-
parison with the model presented here in Table 3 (“new model”): 
application to a subset of subjects from the validation cohort for 
whom both scores could be calculable on the basis of the available 
information.
Supplementary Methods S1. Methods.
Supplementary Material S1. Discussion and SAS code.
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